Medrad preps personalized protocols for ECRCAD firm readies lymph node software for ECRHitachi sets ECR showcase
Medrad will demonstrate at the European Congress of Radiology in Vienna works-in-progress that promise to take its P3T family of patient protocol software beyond cardiac CT. The current product uses patient-specific parameters to personalize cardiac CT protocols for the injection of contrast. Clinical research has demonstrated that these cardiac protocols help in the assessment of pulmonary embolism by providing better contrast enhancement of the pulmonary arteries.
Definiens will launch a new CAD application later this week at the European Congress of Radiology. LymphExpert helps detect the metastatic spread of cancer by better identifying, analyzing, and measuring volumetric changes in the size of lymph nodes. The CAD software promises to save time and make study results more consistent by automating segmentation and analysis of the nodes. LymphExpert is brought in after a radiologist has manually detected lymph nodes in a CT image, automatically segmenting and quantifying the nodes according to established guidelines, then reconstructing a volumetric image. Definiens contends that a precise 3D picture of a lymph node's growth or shrinkage over time indicates cancer progression or remission. The Munich-based company, founded in 1986 by Nobel Laureate Gerd Binnig, develops "cognitive emulation" software that automates and quantifies challenging image analysis challenges.
Patient- and operator-friendly technology will take center stage in the Hitachi Medical booth during the European Congress of Radiology. The Japanese company will highlight a new ultrasound system, elastography, and its latest developments in high-field open MR. Hitachi will tout the new Hi Vision Preirus ultrasound system for the flexibility and comfort it provides the practitioner. HI-RTE (Hitachi Real-Time Tissue Elastography) will be presented as the means for differentiating cancerous from healthy tissue by making reliable assessments and offering real-time color display of tissue elasticity. The 1.2T Oasis will be framed as the most powerful and patient-friendly open MRI in the global marketplace.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.